A Phase 1 Study of the CD40 Agonist MEDI5083 in Combination with Durvalumab in Patients with Advanced Solid Tumors
Immunotherapy（2024）
Key words
CD40,CD40L,cancer,efficacy,fusion protein,safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined